Form 4 for MAIA MAIA Biotechnology, Inc.

Accepted 2024-03-15 00:00:00 ET · period of report 2024-03-14 · accession 0001127602-24-010327 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2024-03-15	2024-03-14	MAIA	Smith Stan	Dir	P - Purchase	$1.17	+170.9K	857.6K	+25%	+$200.0K
DI	2024-03-15	2024-03-14	MAIA	Smith Stan	Dir	P - Purchase	$1.30	+170.9K	170.9K	New	+$222.2K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-03-14	P	A	170,940	$1.17	857,568	I See Footnote	—	—	(F1) The common stock was purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. (F2) These securities are beneficially owned by Mr. Smith through The Stan V. Smith Trust Dated 1993.
2	Derivative	Warrants	2024-03-14	P	A	170,940	$1.30	170,940	I See Footnote	$1.30 · 2024-09-14 to 2029-09-14	170,940 Common Stock	(F4) These securities are beneficailly owned by Mr. Smith through The Stan V. Smith Trust Dated 1993. (F3) The warrants were purchased pursuant to a Securities Purchase Agreement dated March 11, 2024 and were deemed options issued under the Issuer's 2021 Equity Incentive Plan on March 14, 2024. The options are exercisable beginning on the six month anniverary of the issuance date and expire 5-years after the initial exercise date.